Maintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong Prospects

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report) today and set a price target of $14.00.

Yi Chen has given his Buy rating due to a combination of factors including Ocular Therapeutix’s recent financial growth and promising clinical trial advancements. Ocular Therapeutix reported a 10.5% year-over-year increase in revenue for the first quarter of 2024, surpassing estimates. Furthermore, the company has shown progress in its clinical trials, particularly with AXPAXLI, which has moved into the pivotal Phase 3 trials for the treatment of wet age-related macular degeneration (AMD). The company’s strategy update is highly anticipated at the upcoming investor day, which may reveal further insights into its potential growth trajectory.

The positive momentum of Ocular Therapeutix is further supported by the initiation of patient randomization in the Phase 3 SOL-1 trial of AXPAXLI, demonstrating a significant step forward in its development. The trial’s design, approved by the FDA, aims to recruit around 300 subjects and includes an innovative approach to patient enrollment criteria. Additionally, the company has shown encouraging results from other clinical programs, which strengthens the case for its long-term value proposition. Consequently, Yi Chen’s adjusted price target of $14, despite a slight decrease from the previous target, reflects confidence in the company’s market valuation and its prospects, maintaining the Buy recommendation.

According to TipRanks, Chen is an analyst with an average return of -23.7% and a 26.65% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Aslan Pharmaceuticals, and Icecure Medical.

In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $22.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Ocular Therapeutix (OCUL) Company Description:

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.